OOIR: Observatory of International Research

Papers

(The H4-Index of Diabetes Technology & Therapeutics is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology	136
Glycemic Control in Type 1 Diabetes Mellitus During COVID-19 Quarantine and the Role of In-Home Physical Activity	120
Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities	118
Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users	113
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes	113
HbA1c Levels in Type 1 Diabetes from Early Childhood to Older Adults: A Deeper Dive into the Influence of Technology and Socioeconomic Status on HbA1c in the T1D Exchange Clinic Registry Findings	100
Racial–Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes	93
Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology	91
The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth	84
Inpatient Transition to Virtual Care During COVID-19 Pandemic	82
The Digital/Virtual Diabetes Clinic: The Future Is Now—Recommendations from an International Panel on Diabetes Digital Technologies Introduction	79
A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System	76
Cost, Hassle, and On-Body Experience: Barriers to Diabetes Device Use in Adolescents and Potential Intervention Targets	73
The SWEET Project 10-Year Benchmarking in 19 Countries Worldwide Is Associated with Improved HbA1c and Increased Use of Diabetes Technology in Youth with Type 1 Diabetes	65
Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen	61
Remote Application and Use of Real-Time Continuous Glucose Monitoring by Adults with Type 2 Diabetes in a Virtual Diabetes Clinic	61
Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes	60
Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes	57
Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial	56
First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes	54
Glucose Time In Range, Time Above Range, and Time Below Range Depend on Mean or Median Glucose or HbA1c, Glucose Coefficient of Variation, and Shape of the Glucose Distribution	52
The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis	51
Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Ov	48
Adoption of Telemedicine for Type 1 Diabetes Care During the COVID-19 Pandemic	48
Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes	47

Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes	47
The Effectiveness of Virtual Training on the MiniMed™ 670G System in People with Type 1 Diabetes During the COVID-19 Pandemic	46
HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis	45
Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study	45
Time In Range in Children with Type 1 Diabetes Using Treatment Strategies Based on Nonautomated Insulin Delivery Systems in the Real World	43
A Three-Way Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense Continuous Glucose Monitoring Devices in a Home-Use Study of Subjects with Type 1 Diabetes	42
Acceptability and Utilization of Newer Technologies and Effects on Glycemic Control in Type 2 Diabetes: Lessons Learned from Lockdown	42
Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes	42
Top 10 Tips for Successfully Implementing a Diabetes Telehealth Program	42
Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features	41
Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes	40
Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and Their Parents	40
Implicit Racial–Ethnic and Insurance-Mediated Bias to Recommending Diabetes Technology: Insights from T1D Exchange Multicenter Pediatric and Adult Diabetes Provider Cohort	38
Managing Diabetes in Pregnancy Before, During, and After COVID-19	38